Comphya appoints Mikael Sturny as Chief Technology Officer.
02 October 2020
Lausanne, Switzerland, September 22, 2020 – Comphya SA, the developer of CaverSTIM, announced today the appointment of Mikael Sturny as Chief Technology Officer. Mikael is a co-founder of Comphya and has been contributing to the company development since its embryonic stages. Now, after concluding his Ph.D., Mikael will join Comphya full-time to support the company’s mission to bring a superior alternative to treat erectile dysfunction in patients non-responsive to oral drugs.
Mikael has dedicated several years to the MedTech area, particularly in the neuromodulation field. His Ph.D. thesis was dedicated to the development of novel strategies for the treatment of erectile dysfunction, with a particular focus on the usage of neuromodulation principles. A large part of his studies concentrated on demonstrating the flexible electrode-array concept, Comphya’s core technology, in humans, which showed the proof of concept and technology feasibility. Also, Mikael’s study shows that the use of low-intensity electrostimulation may also promote nerve regeneration and natural function recovery, pointing out additional benefits of neuromodulation in the treatment of post-prostatectomy erectile dysfunction.
Mikael will support Comphya through upcoming product development, clinical trials, and market approval. “We are very much pleased to have Mikael, he is essential for Comphya’s technology development. With his dedication and experience he greatly strengthens our team for our next exciting steps”, said Rodrigo Fraga-Silva, CEO and co-founder of Comphya.
“I am very thrilled to join Comphya, now full-time, and support the development of a novel therapeutic tool that will positively impact and benefit many erectile dysfunction patients and their partners”, Mikael commented.
“Mikael’s scientific and technical skills are a tremendous asset for Comphya. Happy to have Mikael full time on board to continue the exciting development of the CaverSTIM“, added Nikos Stergiopulos CSO and co-founder of Comphya.
CaverSTIM is the first implantable neurostimulator to restore erectile function, focused on non-responders to oral drugs. CaverSTIM is a neurostimulator with electrodes to be implanted in the pelvic cavity, which will activate and restore the neuronal path for penile erection. The technology consists of transmitting by radiofrequency operating instructions to the implantable unit, using an external control unit. The system includes two paddle leads with 12 electrodes each (2×12) and connects to an Implanted Pulse Generator (IPG) to deliver electrical stimulation. The IPG, placed subcutaneously in the lower abdomen, is wirelessly programmed using a Clinician Programmer Application to enable the appropriate sets of electrodes and program the stimulation pulse sequence. The patient can turn stimulation on/off, adjust the amplitude, or select pre-defined stimulation pulse sequences using a Patient Remote Control. The IPG is periodically recharged using the external wireless Charger.
About Comphya SA
Comphya is a medical device company based in Lausanne, Switzerland, developing a novel implantable device to restore erectile function in patients non-responsive to oral drugs (e.g., Viagra), particularly spinal cord injury and post-prostatectomy patients. Today, these patients resort to intrapenial injections or penile implants, which are the only available yet painful, problematic and outdated therapies.
Comphya’s patented solution is based on neuroprosthetic principles and offers a unique and superior treatment for erectile dysfunction. The system stimulates the cavernosal nerve (pro-erectile nerve) via external wireless controllers, to restore natural penile erection. The company’s goal is to offer physiological sexual function and quality of life to large parts of the male population in great need.
Rodrigo Fraga-Silva, PhD
CEO & Co-founder